CLAIMS

1. Use of plinabulin, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for reducing neutropenia, wherein the neutropenia is induced by administration of a first chemotherapeutic composition comprising one or more chemotherapeutic agents, wherein the first chemotherapeutic composition does not comprise a taxane,

wherein, the first chemotherapeutic composition comprises one or more agents selected from the group consisting of cyclophosphamide, ifosamide, cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, satraplatin, topotecan, irinotecan, doxorubicin, epirubicin, daunorubicin, valrubicin, and pharmaceutically acceptable salts thereof.

2. The use according to claim 1, wherein the medicament is for use in combination with one or more additional chemotherapeutic compositions.

3. The use according to claim 1 or 2, wherein the first chemotherapeutic composition comprises a single chemotherapeutic agent.

4. The use according to claim 1 or 2, wherein the first chemotherapeutic composition comprises two or more chemotherapeutic agents.

5. The use according to any one of claims 1 to 4, wherein the first chemotherapeutic composition comprises cyclophosphamide.

6. The use according to any one of claims 1 to 4, wherein the first chemotherapeutic composition comprises cisplatin.

7. The use according to any one of claims 1 to 4, wherein the first chemotherapeutic composition comprises doxorubicin.

8. The use according to any one of claims 1 to 4, wherein the first chemotherapeutic composition comprises topotecan.

9. The use according to any one of claims 1 to 8, comprising administering plinabulin prior to administering the first chemotherapeutic composition.

10. The use according to claim 9, wherein the plinabulin is to be administered in the range of about 1 minute to 24 hours prior to administration of the first chemotherapeutic composition.

11. The use according to any one of claims 1 to 8, comprising administering plinabulin after administering the first chemotherapeutic composition.

12. The use according to claim 11, wherein the plinabulin is to be administered in the range of about 1 minute to 24 hours after administration of the first chemotherapeutic composition.

13. The use according to claim 1 to 8, wherein the plinabulin and the first chemotherapeutic composition are to be administered substantially simultaneously.

14. The use according to claim 1:

the use of plinabulin, or the pharmaceutically acceptable salt thereof, is to be prior to the administration of the first chemotherapeutic composition; and

the use of the additional one or more chemotherapeutic compositions is after the administration of the first chemotherapeutic composition.

15. The use according to claim 1:

the use of the first chemotherapeutic composition is to be prior to the administration of the plinabulin; and

the use of the additional one or more chemotherapeutic compositions is to be after the administration of the plinabulin.

16. Plinabulin for use of claim 1:

the use of the first chemotherapeutic composition is to be prior to the administration of the additional one or more chemotherapeutic compositions; and

the use of the plinabulin is to be after the administration of the additional one or more chemotherapeutic agents.

17. The use according to claims 14 to 16, wherein a period of time between administration of each of plinabulin, the first chemotherapeutic composition, and the additional one or more chemotherapeutic compositions is to be independently selected between about 1 minute and 24 hours.

18. The use according to any one of claims 1 to 17, wherein the neutropenia induced by the first chemotherapeutic composition is a grade 3 or 4 neutropenia.

19. The use according to any one of claims 1 to 18, wherein the reduction of neutropenia comprises a reduction of the likelihood of onset of neutropenia, or a reduction of the severity of neutropenia.